News Sentiment

MIST sentiment intelligence

Milestone Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.28 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-3.0% over one week, +0.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -3.0% Price reacting lower
Trend fit Trend inactive 0.8% over four weeks
Fair value -31.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 46
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
TradingView 9
simplywall.st 5
TradingKey 3
Seeking Alpha 2
GlobeNewswire 2
The Manila Times 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 21
Analyst action 5
Regulatory and legal 3
Deals and strategy 2
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
TradingView Direct company coverage

Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST

This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed, and no trades have occurred. The content appears to be a basic financial data dis

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:11
Source
TradingView
TradingKey Direct company coverage

Milestone Pharmaceuticals Inc (MIST) Institutional Confidence

Milestone Pharmaceuticals Inc (MIST) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 48.38% quarter-over-quarter to 25.86%. Steven Cohen is the largest insti

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 08:10
Source
TradingKey
The Manila Times Direct company coverage

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Inc. announced the grant of 288,000 stock options to six new employees under its 2021 Inducement Plan. These options, granted on July 1, 2026, have an exercise price of $1.32 per share, and will vest over four years, with 25% vesting after one year and t

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:10
Source
The Manila Times
Stock Titan Direct company coverage

Milestone lures six new employees with 288,000 options

Milestone Pharmaceuticals (Nasdaq:MIST) has granted a total of 288,000 stock options to six new employees as a material inducement for their hiring, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on July 1, 2026, have an exercise price of $1.32 per share,

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 02:09
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST

This article provides financial information for Milestone Pharmaceuticals Inc. (NASDAQ: MIST), specifically focusing on its enterprise value to EBIT forward. It is presented in the context of TradingView's platform, offering various financial tools and market data services.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 17:43
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST

The article provides the "Price to sales forward" value for Milestone Pharmaceuticals Inc. (NASDAQ: MIST). It lists the period, value, change, and percentage change for this financial metric. The content focuses solely on these financial details for the company.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – BOATS:MIST

This article provides financial information for Milestone Pharmaceuticals Inc. (MIST) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward, with a data table showing the period, value, and change.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. – BOATS:MIST

This article focuses on the enterprise value to revenue forward metric for Milestone Pharmaceuticals Inc. (MIST) as presented on the Blue Ocean Alternative Trade System (BOATS) within TradingView. It provides a snapshot of MIST's financial data with a focus on this specific valua

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST)

This article provides an overview of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) financial data and analyst estimates. It covers the stock's current price, performance over various periods, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnin

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 08:09
Source
TradingView
TradingView Direct company coverage

MIST Forecast — Price Target — Prediction for 2027

Milestone Pharmaceuticals Inc. (MIST) has a current stock price of 1.25 USD. Analysts have provided price forecasts for MIST, with a max estimate of 8.00 USD and a min estimate of 2.00 USD. The company's financials include a market capitalization of 155.62M USD and upcoming earni

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 19:41
Source
TradingView
TradingKey Direct company coverage

Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Milestone Pharmaceuticals Inc (MIST) as of June 2026. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The stock was trading at $1.3

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 22:39
Source
TradingKey
TradingKey Direct company coverage

Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates

Milestone Pharmaceuticals Inc (MIST) has an earnings forecast score of 8.00 and an average price target of $4.00 from six analysts, with a "Buy" trend. The company's expected revenue for the next quarter is $1.10 million, and its EPS for the previous quarter was -$0.16, with an e

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 11:12
Source
TradingKey
Stock Titan Direct company coverage

Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC

Milestone Pharmaceuticals shareholders approved an amendment to its 2019 Equity Incentive Plan, increasing authorized ordinary shares by 6,800,000 for future equity-based compensation. They also elected all eight director nominees, ratified PricewaterhouseCoopers LLP as the compa

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 20:06
Source
Stock Titan
Stock Titan Direct company coverage

Milestone (NASDAQ: MIST) director receives 77,000 stock options grant

Milestone Pharmaceuticals Inc. director Lisa M. Giles was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully by the next annual stockholder

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Milestone Pharmaceuticals (MIST) awards director 77,000 stock options

Milestone Pharmaceuticals Inc. (MIST) director Duty Stuart was granted 77,000 stock options with an exercise price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the nex

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22

Milestone Pharmaceuticals director Michael John Tomsicek was granted 77,000 stock options at an exercise price of $1.22 per share. These options will vest in twelve equal monthly installments starting July 10, 2026, and will be fully vested by the next annual stockholders’ meetin

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike

Milestone Pharmaceuticals director Seth H. Z. Fischer was granted 77,000 stock options with a strike price of $1.22 per share, expiring on June 10, 2036. The options will vest in twelve equal monthly installments starting July 10, 2026, or fully vest at the next annual shareholde

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 19:39
Source
Stock Titan
Finviz Direct company coverage

MIST - Milestone Pharmaceuticals Inc Stock Price and Quote

This article provides a comprehensive overview of Milestone Pharmaceuticals Inc. (MIST), including its stock price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's focus on developing cardiovascular medicines, particula

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jun 2026 04:39
Source
Finviz
PR Newswire Direct company coverage

Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org

The Heart Rhythm Society (HRS) and Milestone Pharmaceuticals have partnered to expand patient education for supraventricular tachycardia (SVT) through the UpBeat.org platform. This initiative, launched in recognition of SVT Awareness Day, provides new resources like info sheets,

Tone
Positive 73/100
Event
Market update
Published
01 Jun 2026 21:40
Source
PR Newswire
Stock Titan Direct company coverage

[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing

This article reports on a Milestone Pharmaceuticals Inc. (MIST) SEC Filing, Form EFFECT, which became effective on May 22, 2026, at 4:00 P.M. The filing is a Notice of Effectiveness for an S-3 Shelf Registration Statement. The article also provides recent news and SEC filings rel

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 10:38
Source
Stock Titan
Stock Titan Direct company coverage

RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership

RTW Investments and Roderick Wong have disclosed a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. (MIST). This ownership includes 12,356,953 common shares, with the percentage calculated based on 117,667,277 shares outstanding as of March 20, 2026. The filing

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 12:10
Source
Stock Titan
Simply Wall Street Direct company coverage

Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company, is projected to reach profitability by 2028, overcoming current losses of US$68 million. Analysts anticipate a final loss in 2027 before the company turns a profit of US$14 million in 2028, requiring an am

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 11:10
Source
Simply Wall Street